Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a study titled A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy. The study aims to assess the safety and effectiveness of the pozelimab and cemdisiran combination in treating Paroxysmal Nocturnal Hemoglobinuria (PNH) compared to existing treatments ravulizumab and eculizumab.
The intervention involves testing a combination of two experimental drugs, pozelimab and cemdisiran, administered intravenously and subcutaneously. The purpose is to determine their efficacy and safety in comparison to established treatments for PNH.
This Phase 3 study is interventional, with a randomized, parallel assignment model and no masking. The primary purpose is treatment-focused, aiming to provide insights into the new drug combination’s potential benefits over existing therapies.
The study began on November 12, 2021, with the latest update submitted on August 27, 2025. These dates are crucial as they mark the study’s progression and ongoing recruitment status, indicating active research and potential future developments.
For investors, this study represents a significant opportunity for Regeneron Pharmaceuticals to strengthen its position in the PNH treatment market. Positive outcomes could enhance stock performance and investor confidence, especially given the competitive landscape with existing treatments from other pharmaceutical companies.
The study is currently ongoing, with updated details available on the ClinicalTrials portal.